Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233)

British Journal of Cancer

Volumn 72, Issue 5, 1995, Pages 1144-1150

  Patterson, A V ^a,b   Barham, H M ^a   Chinje, E C ^a   Adams, G E ^a   Harris, A L ^b   Stratford, I J ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bioreductive drugs; Breast cancer; Hypoxia; P450 reductase; Tirapazamine

Indexed keywords

3 AMINO 1,2,4 BENZOTRIAZINE 1 OXIDE; CYTOCHROME P450 REDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TIRAPAZAMINE;

ARTICLE; BREAST ADENOCARCINOMA; DRUG METABOLISM; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; BREAST NEOPLASMS; CELL HYPOXIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE, NEOPLASM; HUMAN; NADPH-FERRIHEMOPROTEIN REDUCTASE; OXIDATION-REDUCTION; OXIDOREDUCTASES; OXYGEN; PRODRUGS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0028867912     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1995.478     Document Type: Article

References (64)

1. ADAMS GE. (1976). Hypoxic cell sensitizers for radiotherapy. In Cancer, a Comprehensive Treatise, Vol. 6, Radiotherapy, Surgery and Immunotherapy. Becker FF. (ed.) pp. 181-223. Plenum Press, New York.
2. ADAMS GE and STRATFORD U. (1986). Hypoxia-mediated nitroheterocyclic drugs in the radio and chemotherapy of cancer An overview. Biochem. Pharmacol., 35, 71–76.
3. ADAMS GE and STRATFORD U. (1994). Bioreductive drugs for cancer therapy: The search for tumour specificity. Int. J. Radiat. Oncol. Biol. Phys., 29, 231–238.
4. BAILEY SM, LEWIS AD and WORKMAN P. (1994). Involvement of NADPH: Cytochrome P450 reductase in activation of E09 to a DNA damaging species. Br. J. Cancer, 69, (suppl. XXI), 57.
5. BAKER MA ZEMAN EM, HIRST VK and BROWN JM. (1988). Metabolism of SR 4233 by Chinese Hamster ovary cells: Rask of selective hypoxic cytotoxicity. Cancer Res., 48, 5947–5952.
6. BIEDERMANN KA WANG J, GRAHAM RP and BROWN JM. (1991). SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures. Br. J. Cancer, 63, 358–362.
7. BROWN JM. (1993). SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer, 67, 1163–1170.
8. BROWN JM and LEMMON MJ. (1990). Potentation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumours. Cancer Res., 50, 7745–7749.
9. BRADFORD M. (1976). A rapid and sensitive method for quantification of microgram quantities of protein utilising the principle of protein dye binding. Anal. Biochem., 72, 248–254.
10. CAHILL A and WHITE INH. (1990). Reductive metabolism of 3-amino-1, 2, 4-benzotriazine-1, 4-dioxide (SR 4233) and the induction of unscheduled DNA synthesis in rat and human derived cell lines. Carcinogenesis, 11, 1407–1411.
11. CARMICHAEL J, DE GRAFF WG, GAZDAR AF, MINNA JD and MITCHELL JB. (1987). Evaluation of a tetrazohum-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res., 47, 936–941.
12. CHAPLIN DJ, HORSMAN MR and AOKI DS. (1991). Nicotinamide, Fluosol DNA and Carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo. Br. J. Cancer, 63, 109–113.
13. COLE S, STRATFORD U, ADAMS GE, FIELDEN EM and JENKINS TC. (1990). Dual function 2-nitroimidazoles and hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas. Radiat. Res., 124, S38-S43.
14. COLE S, STRATFORD U, BOWLER J, NOLAN J, WRIGHT EG, LORIMORE SA and ADAMS GE. (1991). Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration of mice. Int. J. Radiat Oncol. Biol. Phys., 21, 387–395.
15. COLE S, STRATFORD U, FIELDEN EM, ADAMS GE, LEOPOLD W, ELLIOT W, SUTO M and SEBOLT-LEOPOLD J. (1992). Dual function nitroimidazoles less toxic than RSU 1069: Selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908). Int. J. Radiat. Oncol. Biol. Phys., 22, 545–548.
16. FITZSIMMONS SA, LEWIS AD, RILEY RJ and WORKMAN P. (1994). Reduction of 3-amino-1, 2, 4-benzotriazine-1, 4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH: cytochrome P450 oxidoreductase. Carcinogenesis, 15, 1503–1510.
17. GATENBY RA, KESSLER HB, ROSENBLUM JS, COIA LR, MOLDOFSKY PJ, HARTZ WH and BRODER GJ. (1988). Oxygen distribution in squamous cell carcinoma metastases and its relationship to the outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 14, 831–838.
18. HENDRIKS, HR, PIZAO PE, BERGER DP, KOOISTRA KL, BIBBY MC, BOVEN E, DREEF-VAN DER MEULEN HC, HENRAR REC, FIEBIG HH, DOUBLE JA, HORNSTRA HW, PINEDO HM, WORKMAN P and SCHWARTSMANN G. (1993). E09: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur. J. Cancer, 29A, 897–906.
19. HERSCHER LL, KRISHNA MC, COOK JA, COLEMAN CN, BLAGLOW JE, TUTTLE SW, GONZALEZ FJ and MITCHELL JB. (1994). Protection against SR 4233 (Tirapazamine) aerobic cytotoxicity by the metal chelators desferrioxamine and tiron. Int. J. Radiat. Oncol. Biol. Phys., 30, 879–885.
20. HOCKEL M, SCHLENGER K, KNOOP C and VAUPEL P. (1991). Oxygenation of carcinomas of the uterine cervix: evaluation by computerised O2 tension measurements. Cancer Res., 51, 6098–6102.
21. HOCKEL M, KNOOP C, SCHLENGER K, VORNDRAN B, BAUSSMAN E, MITZE M, KNAPSTEIN PG and VAUPEL P. (1993). Intratumoral PO2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol., 26, 45–50.
22. HODNICK WF and SARTORELLI AC. (1993). Reductive activation of mitomycin C by NADH: cytochrome b5 reductase. Cancer Res., 53, 4907–4912.
23. JENKINS TC, NAYLOR MA O’NEILL P, THREADGILL MD, COLE S, STRATFORD U, ADAMS GE, FIELDEN EM, SUTO MJ and STIER MA (1990). Synthesis and evaluation of 1 -3-(2-haloethylamino)-propyl-2-nitroimidazoles as pro-drugs of RSU 1069 and its analogues, which are radiosensitizers and bioreductively activated cytotoxins. J. Med. Chem., 33, 2603–2610.
24. KENNEDY KA (1987). Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Des., 2, 181–194.
25. KEOHANE A GODDEN J, STRATFORD U and ADAMS GE. (1990). The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR 4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation. Br. J. Cancer, 61, 722–726.
26. KOCH CJ. (1993). Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res., 53, 3992–3997.
27. LADEROUTE K, WARDMAN P and RAUTH AM. (1988). Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1, 2, 4-benzotriazine-1, 4-Dioxide (SR 4233). Biochem. Pharmacol., 37, 1487–1495.
28. LARTIGAU E, MARTIN L, LAMBIN P, HEIE-MEDER C, GERBAULET A, ESCHWEGE F and GUICHARD M. (1992). Mesure de la pression partielle en oxygene dans des tumeurs du col uterin. Bull. Cancer/Radiotherapie, 79, 199–206.
29. LIN AJ, COSBY LA, SHANSKY CW and SARTORELLI AC. (1972). Potential bioreductive alkylating agents. I, Benzoquinone derivatives. J. Med. Chem., 15, 1247–1252.
30. LLOYD RV, DULING DR, RUMYANTSEVA GV, MASON RP and BRIDSON PR. (1991). Microsomal reduction of 3-amino-1, 2, 4-benzotriazine 1, 4-dioxide to a free radical. Mol. Pharmacol., 40, 440–445.
31. MOSSMAN T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55–61.
32. MOULDER JE and ROCKWELL S. (1987). Tumor hypoxia: its impact on cancer therapy. Cancer Metast. Rev., 5, 313–341.
33. MURRAY GI, FOSTER CO, BARNES TS, WEAVER RJ, EWEN SWB, MELVIN WT and BURKE MD. (1991). Expression of cytochrome P450IA in breast cancer. Br. J. Cancer, 63, 1021–1023.
34. OKUNIEFF P, HOECKEL M, DUNPHY EP, SCHLENGER K, KNOOP C and VAUPEL P. (1993). Oxygen tension distributions are sufficient to explain the local response of human breast tumours treated with radiation alone. Int. J. Radiat. Oncol. Biol. Phys. 26, 631–636.
35. PAINE AJ. (1990). The maintainanee of cytochrome P-450 in rat hepatocyte culture: some applications of liver cell cultures in the study of drug metabolism, toxicity and induction of the P-450 system. Chem. Biol. Interact., 74, 1–31.
36. PATTERSON AV, ROBERTSON N, HOULBROOK S, STEPHENS MA, ADAMS GE, HARRIS AL, STRATFORD U and CARMICHAEL J. (1994). The role of DT-diaphorase in determining the sensitivity of human tumour cells to tirapazamine (SR 4233). Int. J. Radiat. Oncol. Biol. Phys., 29, 369–372.
37. PETERSON AJ and PROUGH RA. (1986). Cytochrome P450 reductase and cytochrome b5 in cytochrome P450 catalysis. In Cytochrome P450: Structure, Mechanism and Biochemistry, Oritz de Montellano, RP. (ed.) pp. 89-119. Plenum Press: New York.
38. PHILIP AP, KAKLAMANIS L, RYLEY N, STRATFORD U, WOLF R, HARRIS A and CARMICHAEL J. (1994). Expression of xenobiotic-metabolizing enzymes by primary and secondary hepatic tumours in man. Int. J. Radiat. Oncol. Biol. Phys., 29, 277–283.
39. PLUMB JA, MILROY R, and KAYE SB. (1989). Effects of the pH dependence of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide-formazan absorption on chem6sensitivity determined by a novel tetrazoliurn-based assay. Cancer Res., 49, 4435–4440.
40. PLUMB JA, GERRITSEN M, MILROY R, THOMSON P and WORKMAN P. (1994). Relative importance of DT-diaphorase and hypoxia in the bioactivation of E09 by human lung tumour cell lines. Int. J. Radiat. Oncol. Biol. Phys., 29, 295–299.
41. RAMPLING R, CRUICKSHANK G, LEWIS AD, FITZSIMMONS SA and WORKMAN P. (1994). Direct measurement of p02 distribution and bioreductive enzymes in human malignant brain tumours. Int. J. Radiat. Oncol. Biol. Phys., 29, 427–431.
42. RILEY JR, HEMINGWAY SA, GRAHAM MA and WORKMAN P. (1993). Initial characterisation of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1, 2, 4-benzotriazine-1, 4-DI-N-Oxide (Tirapazamine, SR 4233, WIN 59075). Biochem. Pharmacol., 45, 1065–1077.
43. ROBERTSON N, STRATFORD U, HOULBROOK S, CARMICHAEL J and ADAMS GE. (1992). The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase? Biochem. Pharmacol., 44, 409–412.
44. ROBERTSON N, HAIGH N, ADAMS GE and STRATFORD U. (1994). Factors affecting sensitivity to E09 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur. J. Cancer, 30 A, 1013–1019.
45. ROCKWELL S and MOULDER JE. (1990). Hypoxic fractions of human tumours xenografted into mice: a review. Int. J. Radiat. One. Biol. Phys., 19, 197–202.
46. ROCKWELL S, KEYES SR and SARTORELLI AC. (1988). Preclinical studies of porfiromycin as an adjunct to radiotherapy. Rad. Res., 116, 100–113.
47. SENG F and LEY K. (1972). Simple synthesis of 3-amino-1, 2, 4 benzotriazine 1, 4-dioxide. Angew. Chem. Int., XI, 1009–1010.
48. SMITH G, HARRISON DJ, EAST N, RAE F, WOLF H and WOLF CR. (1993). Regulation of cytochrome P450 gene expression in human colon and breast tumour xenografts. Br. J. Cancer, 68, 57–63.
49. SMITSKAMP-WILMS E, PETERS GJ, PINEDO HM, VAN ARK-OTTE J and GIACCONE G. (1994). Chemosensitivity to the indoloquinone E09 is correlated with DT-diaphorase activity and its gene expression. Biochem. Pharmacol, 47, 1325–1332.
50. SOULE D, VAZQUEZ J, LONG A, ALBERT S and BRENNAN M. (1973). A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst., 51, 1409–1413.
51. STRATFORD U. (1992). Concepts and developments in radiosensitization of mammalian cells. Int. J. Radiat. Oncol. Biol. Phys., 22, 529–532.
52. STRATFORD U and STEPHENS MA. (1989). The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int. J. Radiat. Oncol. Biol. Phys., 16, 973–976.
53. STRATFORD U, O’NEILL P, SHELDON PW, SILVER ARJ, WALLING JM and ADAMS GE. (1986). RSU 1069. A nitroimidazole containing an aziridine group -bioreduction greatly increases cytotoxicity under hypoxic conditions. Biochem. Pharmacol., 35, 105–109.
54. VAUPEL P, SCHLENGER K, KNOOP C and HOCKEL M. (1991). Oxygenation of human tumours: evaluation of tissue oxygen distribution in breast cancers by computerised 02 tension measurements. Cancer Res., 51, 3316–3322.
55. WALTON MI and WORKMAN P. (1987). Nitroimidazole bioreductive metabolism: quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochem. Pharmacol., 36, 887–896.
56. WALTON MI and WORKMAN P. (1990). Enzymology of the reductive activation of SR4233: A novel benzotriazene di-N-oxide hypoxic cell cytotoxin. Biochem. Pharmacol., 39, 1735–1742.
57. WALTON MI, WOLF CR and WORKMAN P. (1989). Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int. J. Radiat. Oncol. Biol. Phys., 16, 983–986.
58. WALTON MI, WOLF CR and WORKMAN P. (1992). The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine DI-N-Oxide hypoxic cytotoxin 3-amino-1, 2, 4-benzotriazine-1, 4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem. Pharmacol., 44, 251–259.
59. WANG J, BIEDERMANN KA, WOLF CR and BROWN JM. (1993). Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies. Br. J. Cancer, 67, 321–325.
60. WORKMAN P. (1992). Bioreductive mechanisms. Int. J. Radiat. Oncol. Biol. Phys., 22, 631–637.
61. WORKMAN P. (1994). Enzyme-directed bioreductive drug development revisited. Oncology Res., 6, 461–475.
62. WORKMAN P and STRATFORD U. (1993). The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metas. Rev., 12, 73–82.
63. WORKMAN P and WALTON MI. (1986). Enzyme-directed bioreductive drug development. In Selective Activation of Drugs by Redox Processes, Adams GE, Beccia A, Fielden EM and Wardman P. (eds.) pp. 89-112. Plenum Press: New York.
64. ZEMAN EM, BROWN JM, LEMMON MJ, HIRST VK and LEE WW. (1986). SR 4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys., 12, 1239–1242.